These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16110617)

  • 1. Retargeting T cells and immune effector cells with bispecific antibodies.
    Lum LG; Davol PA
    Cancer Chemother Biol Response Modif; 2005; 22():273-91. PubMed ID: 16110617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting T cells with bispecific antibodies for cancer therapy.
    Lum LG; Thakur A
    BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new face of bispecific antibodies: targeting cancer and much more.
    Lum LG; Davol PA; Lee RJ
    Exp Hematol; 2006 Jan; 34(1):1-6. PubMed ID: 16413384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
    Patrick TA; Kranz DM; Zachary JF; Roy EJ
    Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
    Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
    J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
    Lum LG; Sen M
    Acta Haematol; 2001; 105(3):130-6. PubMed ID: 11463985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
    Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated T cells armed with bispecific antibodies kill tumor targets.
    Bhutani D; Lum LG
    Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies in cancer immunotherapy.
    Rader C
    Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.